Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.

Marques IDB, Araújo MJCLN, Graciolli FG, Dos Reis LM, Pereira RMR, Alvarenga JC, Custódio MR, Jorgetti V, Elias RM, Moysés RMA, David-Neto E.

J Am Soc Nephrol. 2019 Jan 3. pii: ASN.2018060656. doi: 10.1681/ASN.2018060656. [Epub ahead of print]

PMID:
30606784
2.

A prospective study of the influence of the skeleton on calcium mass transfer during hemodialysis.

Goldenstein PT, Graciolli FG, Antunes GL, Dominguez WV, Dos Reis LM, Moe S, Elias RM, Jorgetti V, Moysés RMA.

PLoS One. 2018 Jul 30;13(7):e0198946. doi: 10.1371/journal.pone.0198946. eCollection 2018.

3.

Effect of Aerobic Exercise on Markers of Bone Metabolism of Overweight and Obese Patients With Chronic Kidney Disease.

Gomes TS, Aoike DT, Baria F, Graciolli FG, Moyses RMA, Cuppari L.

J Ren Nutr. 2017 Sep;27(5):364-371. doi: 10.1053/j.jrn.2017.04.009. Epub 2017 Jun 9.

PMID:
28606422
4.

The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.

Graciolli FG, Neves KR, Barreto F, Barreto DV, Dos Reis LM, Canziani ME, Sabbagh Y, Carvalho AB, Jorgetti V, Elias RM, Schiavi S, Moysés RMA.

Kidney Int. 2017 Jun;91(6):1436-1446. doi: 10.1016/j.kint.2016.12.029. Epub 2017 Mar 18.

PMID:
28318623
5.

Biopsy vs. peripheral computed tomography to assess bone disease in CKD patients on dialysis: differences and similarities.

Marques ID, Araújo MJ, Graciolli FG, Reis LM, Pereira RM, Custódio MR, Jorgetti V, Elias RM, David-Neto E, Moysés RM.

Osteoporos Int. 2017 May;28(5):1675-1683. doi: 10.1007/s00198-017-3956-9. Epub 2017 Feb 16.

PMID:
28204954
6.

Effect of Mineral and Bone Metabolism on Restless Legs Syndrome in Hemodialysis Patients.

Neves PD, Graciolli FG, Oliveira IB, Bridi RA, Moysés RM, Elias RM.

J Clin Sleep Med. 2017 Jan 15;13(1):89-94. doi: 10.5664/jcsm.6396.

7.

Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis.

Resende AL, Elias RM, Wolf M, Dos Reis LM, Graciolli FG, Santos GD, Dias CB, Jorgetti V, Woronik V, Moysés RM.

Cytokine. 2017 Mar;91:124-127. doi: 10.1016/j.cyto.2016.12.022. Epub 2017 Jan 4.

PMID:
28063327
8.

Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis.

Magalhães LP, Dos Reis LM, Graciolli FG, Pereira BJ, de Oliveira RB, de Souza AA, Moyses RM, Elias RM, Jorgetti V.

PLoS One. 2017 Jan 3;12(1):e0167895. doi: 10.1371/journal.pone.0167895. eCollection 2017.

9.

Parathyroidectomy Improves Restless Leg Syndrome in Patients on Hemodialysis.

Santos RS, Coelho FM, da Silva BC, Graciolli FG, Dominguez WV, de Menezes Montenegro FL, Jorgetti V, Moysés RM, Elias RM.

PLoS One. 2016 May 19;11(5):e0155835. doi: 10.1371/journal.pone.0155835. eCollection 2016.

10.

Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?

Moysés RM, Jamal SA, Graciolli FG, dos Reis LM, Elias RM.

Int Urol Nephrol. 2015 May;47(5):847-50. doi: 10.1007/s11255-015-0971-7. Epub 2015 Apr 11.

PMID:
25862239
11.

Serum sclerostin is an independent predictor of mortality in hemodialysis patients.

Gonçalves FL, Elias RM, dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moysés RM.

BMC Nephrol. 2014 Dec 2;15:190. doi: 10.1186/1471-2369-15-190.

12.

Correction of metabolic acidosis in hemodialysis: consequences on serum leptin and mineral metabolism.

Bales AM, Moysés RM, dos Reis LM, Graciolli FG, Hung J, Martins Castro MC, Elias RM.

Int Urol Nephrol. 2015 Jan;47(1):177-82. doi: 10.1007/s11255-014-0844-5. Epub 2014 Sep 25.

PMID:
25252843
13.

Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models.

Ferrari GO, Ferreira JC, Cavallari RT, Neves KR, dos Reis LM, Dominguez WV, Oliveira EC, Graciolli FG, Passlick-Deetjen J, Jorgetti V, Moysés RM.

BMC Nephrol. 2014 May 3;15:69. doi: 10.1186/1471-2369-15-69.

14.

Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, Dos Reis LM, Graciolli FG, Oliveira EC, Liu S, Sabbagh Y, Jorgetti V, Schiavi S, Moysés RM.

PLoS One. 2013 Nov 13;8(11):e79721. doi: 10.1371/journal.pone.0079721. eCollection 2013.

15.

Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.

de Oliveira RB, Graciolli FG, dos Reis LM, Cancela AL, Cuppari L, Canziani ME, Carvalho AB, Jorgetti V, Moysés RM.

Nephrol Dial Transplant. 2013 Oct;28(10):2510-7. doi: 10.1093/ndt/gft234. Epub 2013 Aug 23.

PMID:
23975746
16.

Persistence of bone and mineral disorders 2 years after successful kidney transplantation.

Neves CL, dos Reis LM, Batista DG, Custodio MR, Graciolli FG, Martin Rde C, Neves KR, Dominguez WV, Moyses RM, Jorgetti V.

Transplantation. 2013 Aug 15;96(3):290-6. doi: 10.1097/TP.0b013e3182985468.

PMID:
23823648
17.

Bone plasticity in response to exercise is sex-dependent in rats.

Vicente WS, dos Reis LM, Graciolli RG, Graciolli FG, Dominguez WV, Wang CC, Fonseca TL, Velosa AP, Roschel H, Teodoro WR, Gualano B, Jorgetti V.

PLoS One. 2013 May 31;8(5):e64725. doi: 10.1371/journal.pone.0064725. Print 2013.

18.

Phosphorus is associated with coronary artery disease in patients with preserved renal function.

Cancela AL, Santos RD, Titan SM, Goldenstein PT, Rochitte CE, Lemos PA, dos Reis LM, Graciolli FG, Jorgetti V, Moysés RM.

PLoS One. 2012;7(5):e36883. doi: 10.1371/journal.pone.0036883. Epub 2012 May 10.

19.

Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC.

J Bone Miner Res. 2012 Aug;27(8):1757-72. doi: 10.1002/jbmr.1630.

20.

Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system.

Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V.

Nephrol Dial Transplant. 2012 Apr;27(4):1437-45. doi: 10.1093/ndt/gfr447. Epub 2011 Aug 8.

PMID:
21825304
21.

FGF-23 as a predictor of renal outcome in diabetic nephropathy.

Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moysés RM.

Clin J Am Soc Nephrol. 2011 Feb;6(2):241-7. doi: 10.2215/CJN.04250510. Epub 2010 Oct 21.

22.

Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.

Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, Moysés RM.

Nephron Clin Pract. 2011;117(1):c74-82. doi: 10.1159/000319650. Epub 2010 Aug 4.

PMID:
20689328
23.

The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances.

Batista DG, Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Dominguez WV, Neves CL, Magalhães AO, Custódio MR, Moysés RM, Jorgetti V.

Calcif Tissue Int. 2010 Jul;87(1):60-7. doi: 10.1007/s00223-010-9367-y. Epub 2010 Apr 29.

PMID:
20428857
24.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM.

Clin J Am Soc Nephrol. 2010 Feb;5(2):286-91. doi: 10.2215/CJN.05420709. Epub 2009 Nov 12.

25.

Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia.

Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moysés RM, Jorgetti V.

Nephrol Dial Transplant. 2009 May;24(5):1416-21. doi: 10.1093/ndt/gfn686. Epub 2008 Dec 15.

PMID:
19075196
26.

Vascular calcification: contribution of parathyroid hormone in renal failure.

Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, Custódio MR, Batista DG, Jorgetti V, Moysés RM.

Kidney Int. 2007 Jun;71(12):1262-70. Epub 2007 Apr 4.

27.

Decreased in vitro osteoblast proliferation and low turnover bone disease in nonuremic proteinuric patients.

Dias CB, Dos Reis LM, Caparbo VF, Graciolli FG, Moysés RM, Barros RT, Jorgetti V, Woronik V.

Kidney Int. 2007 Mar;71(6):562-8. Epub 2007 Jan 17.

28.

Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.

Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moysés RM, Jorgetti V.

Kidney Int. 2004 Dec;66(6):2237-44.

Supplemental Content

Loading ...
Support Center